Modified enzymes

US11965183B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11965183-B2
Application numberUS-202117500831-A
CountryUS
Kind codeB2
Filing dateOct 13, 2021
Priority dateOct 7, 2014
Publication dateApr 23, 2024
Grant dateApr 23, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of characterising a target polynucleotide, comprising: (a) contacting the target polynucleotide with a transmembrane pore and a helicase such that the helicase controls the movement of the target polynucleotide through the pore; and (b) taking one or more electrical measurements as the polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the target polynucleotide and thereby characterising the target polynucleotide, wherein the helicase is a DNA-dependent ATPase (Dda) helicase in which: (i) the Dda helicase comprises a sequence that is at least 70% identical to the sequence set forth in SEQ ID NO: 8 and is recombinantly substituted in at least one residue corresponding to at least one of the following amino acid positions in SEQ ID NO: 8 which interacts with one or more nucleotides in single stranded DNA (ssDNA): H82, N88, P89, F98, D121, V150, P152, F240, F276, S287, H396 and/or Y415; and (ii) the part of the Dda helicase which interacts with the transmembrane pore comprises one or more modifications at one or more residues corresponding to a position in SEQ ID NO: 8 selected from the group consisting of: 3, 4, 5, 176, 177, 179, 180, 185, 193, 194, 195, 198, 199, 200, 202, 203, 204, 207, 208, 209, 210, 211, 212, 213, 216, 221, 224, 255, 318, 347, 405, 415, 434, 437, and 438. 2. The method according to claim 1 , wherein the one or more characteristics are selected from (i) the length of the target polynucleotide, (ii) the identity of the target polynucleotide, (iii) the sequence of the target polynucleotide, (iv) the secondary structure of the target polynucleotide and (v) whether or not the target polynucleotide is modified. 3. The method according to claim 2 , wherein the target polynucleotide is modified by methylation, by oxidation, by damage, with one or more proteins or with one or more labels, tags or spacers. 4. The method according to claim 1 , wherein the electrical measurement is a current measurement, an impedance measurement, a tunnelling measurement or a field effect transistor (FET) measurement. 5. The method according to claim 1 , wherein the method comprises: (a) contacting the target polynucleotide with a transmembrane pore and a helicase such that the helicase controls the movement of the target polynucleotide through the pore; and (b) measuring the current passing through the pore as the polynucleotide moves with respect to the pore wherein the current is indicative of one or more characteristics of the target polynucleotide and thereby characterising the target polynucleotide. 6. The method according to claim 1 , wherein the method further comprises a step of applying a voltage across the pore to form a complex between the pore and the helicase. 7. The method according to claim 1 , wherein at least a portion of the polynucleotide is double stranded. 8. The method according to claim 1 , wherein the pore is a transmembrane protein pore or a solid state pore. 9. The method according to claim 8 , wherein the transmembrane protein pore is derived from a hemolysin, leukocidin, Mycobacterium smegmatis porin A (MspA), MspB, MspC, MspD, lysenin, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A, Neisseria autotransporter lipoprotein (NalP) or WZA. 10. The method according to claim 9 , wherein the transmembrane protein is formed of eight identical subunits as shown in SEQ ID NO: 2 or a variant thereof in which one or more of the eight subunits has at least 50% homology to SEQ ID NO: 2 based on amino acid identity over the entire sequence and which has pore activity. 11. The method of claim 1 , wherein in (a) the at least one amino acid interacts with the sugar and/or base of the one or more nucleotides in single stranded DNA (ssDNA) is substituted with an amino acid which comprises a larger side chain (R group), wherein the amino acid with the larger side chain (R group) is a non-natural amino acid, and wherein the amino acid with the larger side chain (R group) is not alanine (A), cysteine (C), glycine (G), selenocysteine (U), methionine (M), aspartic acid (D) or glutamic acid (E). 12. The method of claim 1 , wherein histidine (H) is substituted with arginine (R), lysine (K), glutamine (Q), asparagine (N), phenylalanine (F), tyrosine (Y) or tryptophan (W); asparagine (N) is substituted with arginine (R), lysine (K), glutamine (Q), histidine (H), phenylalanine (F), tyrosine (Y) or tryptophan (W); proline (P) is substituted with arginine (R), lysine (K), glutamine (Q), asparagine (N), threonine (T), histidine (H), tyrosine (Y), phenylalanine (F), tryptophan (W), leucine (L), valine (V), or isoleucine (I); phenylalanine (F) is substituted with arginine (R), lysine (K), histidine (H), tyrosine (Y) or tryptophan (W); aspartic acid (D) is substituted with arginine (R), lysine (K), glutamine (Q), asparagine (N), histidine (H), phenylalanine (F), tyrosine (Y) or tryptophan (W); valine (V) is substituted with arginine (R), or lysine (K), glutamine (Q), asparagine (N), histidine (H), phenylalanine (F), tyrosine (Y), tryptophan (W), isoleucine (I) or leucine (L); serine (S) is substituted with arginine (R), or lysine (K), glutamine (Q), asparagine (N), histidine (H), phenylalanine (F), tyrosine (Y), tryptophan (W), isoleucine (I) or leucine (L); and/or tyrosine (Y) is substituted with arginine (R), lysine (K) or tryptophan (W). 13. The method of claim 1 , wherein the Dda helicase comprises a substitution corresponding to: H82N; H82Q; H82W; N88R; N88H; N88W; N88Y; P89L; P89V; P89I; P89E; P89T; P89F; D121H; D121Y; D121K; V150I; V150L; V150N; V150W; V150H; P152W; P152F; P152Y; P152H; P152I; P152L; P152V; F240W; F240Y; F240H; F276W; F276R; F276K; F276H; S287K; S287R; S287W; S287F; H396Y; H396F; H396Q; H396K; Y415W; Y415R; F98W/H82N; F98W/H82Q; F98W/H82W; F98W/N88R; F98W/N88H; F98W/N88W; F98W/N88Y; F98W/P89L; F98W/P89V; F98W/P89I; F98W/P89T; F98W/P89F; F98W/D121H; F98W/D121Y; F98W/D121K; F98W/V150I; F98W/V150L; F98W/V150N; F98W/V150W; F98W/V150H; F98W/P152W; F98W/P152F; F98W/P152Y; F98W/P152H; F98W/P152I; F98W/P152L; F98W/P152V; F98W/F240W; F98W/F240Y; F98W/F240H; F98W/F276W; F98W/F276R; F98W/F276K; F98W/F276H; F98W/S287K; F98W/S287R; F98W/S287W; F98W/S287F; F98W/H396Y; F98W/H396F; F98W/H396Q; F98W/Y415W; or F98W/Y415R. 14. The method of claim 1 , wherein the Dda helicase further comprises in (i) a substitution of at least one additional amino acid which interacts with one or more phosphate groups in one or more nucleotides in single stranded DNA (ssDNA), wherein the substitution of at least one amino acid which interacts with one or more phosphates in one or more nucleotides in ssDNA: increases the (a) electrostatic interactions, (b) hydrogen bonding and/or (c) cation-pi (cation-π) interactions between the at least one amino acid and the one or more phosphate groups in ssDNA, increases the net positive charge of the position, and/or is with a non-natural amino acid. 15. The method of claim 14 , wherein the at least one amino acid which interacts with one or more phosphates in one or more nucleotides in ssDNA is at a residue corresponding to at least one of H64, T80, S83, N242, K243, N293, T394 and K397 in SEQ ID NO: 8. 16. The method of claim 1 , wherein the Dda helicase comprises substitutions at residues corresponding to: F98/H64, F98/T80, F98/H82, F98/S83, F98/N242, F98/N293, or F98/K397 in SEO ID NO: 8. 17. The method of claim 16 , wherein the substitutions correspond to: F98W/H64N, F98W/H64Q, F98W/H64K, F98

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11965183B2 cover?
The invention relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
Who is the assignee on this patent?
Oxford Nanopore Tech Plc
What technology area does this patent fall under?
Primary CPC classification C12N9/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).